All In MedTech

Device Trial Radar · NCT06796504

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Apr 17, 2026

Primary completion

Dec 31, 2027

Study completion Sep 30, 2030

Sponsor

Lead sponsor
SetPoint Medical CorporationNot on our public-company list
Sponsor type
Industry
First posted
Jan 28, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The MS pilot study will assess the safety and investigate the remyelinating effects of the SetPoint System (study device) in adult patients diagnosed with relapsing-remitting multiple sclerosis (RRMS). The SetPoint System is intended for adjunctive use with standard of care therapy for RRMS. The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 60 participants at up to 10 sites. All eligible participants will undergo the implant procedure. Two-thirds of the participants will receive active stimulation (treatment) and the one-third will receive non-active stimulation (control). Following treatment evaluations at Week 48, there will be a one-way crossover of control subjects to active stimulation and a 48-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

  • Implant ProcedureProcedure

    The SetPoint System (study device)contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

  • Disease-Modifying Therapies (DMTs)Drug

    All subjects will continue treatment with standard of care disease-modifying therapies for the duration of the study.

  • Active stimulationDevice

    Active stimulation for 1 minute once per day

  • Non-active stimulationDevice

    Non-active stimulation for 1 minute once per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Informed consent through Week 96

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Irvine Center for Clinical Research

    Irvine, California · Recruiting

  • Shepherd Center

    Atlanta, Georgia · Recruiting

  • Johns Hopkins School of Medicine

    Baltimore, Maryland · Recruiting

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.